

CURRICULUM VITAE

Stan G. Louie

Business Address: University of Southern California
School of Pharmacy
1985 Zonal Avenue
Los Angeles, California 90033-0804

Business Telephone 323-442-3646

Business Fax 323-442-1435

Email Address slouie@hsc.usc.edu

Education Doctorate of Pharmacy
Conferred 1987
University of California in San Francisco
School of Pharmacy
San Francisco, CA

Bachelor of Science in Biochemistry
Conferred 1982
University of California in Los Angeles
Department of Chemistry and Biochemistry
Los Angeles, CA

Post Graduate Training Pharmacy Resident
Pacific Presbyterian Medical Center
Department of Pharmaceutical Services
San Francisco, CA.
Associate Member of Research
Kuzell Institute/MRI of San Francisco
Pacific Presbyterian Medical Center
San Francisco, CA

Post Graduate Training Continue Sabbatical Training
University of Southern California
School of Pharmacy
Department of Molecular Toxicology
Los Angeles, CA

Professional Experience and Appointments

1999 to present Associate Professor
School of Pharmacy
University of Southern California
Los Angeles, CA 90033

1999 to present Associate Professor of Family Practice
Department of Family Medicine
School of Medicine
University of Southern California
Los Angeles, CA 90022

1996 to present Assistant Professor of Family Practice
Department of Family Medicine
University of Southern California
Los Angeles, CA 90022

1993 to 1999	Assistant Professor of Clinical Pharmacy AIDS Research Unit Los Angeles County AIDS Clinic University of Southern California Los Angeles, CA
1989 to 1993	Assistant Professor of Clinical Pharmacy: Kenneth Norris Cancer Research Institute University of Southern California Los Angeles, CA
1988-1989	Associate of Research/Adjunct Clinical Professor of Pharmacy. Kuzell Institute/MRI of San Francisco University of Pacific Pacific Presbyterian Medical Center San Francisco, CA
1987-1988	Pharmacy Resident Adjunct Lecturer of Pharmacy University of Pacific/Pacific Presbyterian Medical Center San Francisco, CA
1987 to 1989	Pharmacist Consultant Stanford Home Treatment Services/InfusionCare Redwood City, CA

Professional Affiliation:

1999 to Present	Consultant	Pacific AIDS Education Training Center
1998 to present	Director	Jeffrey Goodman Specialty Health Care Clinic
1998 to present	Member	Pharmacy and Therapeutics Member of Jeffery Goodman Health Clinic
1994 to present	Member	Center for Healthcare Outcomes Assessment and Technology Evaluation.
1994 to present	Member	AIDS Research Unit
1989 to 1994	Member	Kenneth Norris Cancer Research Institute
1988-1989	Member	Kuzell Institute/Molecular Research Institute

Professional/Honorary Societies

American Association for the Advancement of Science (AAAS)
California Society of Health-system Pharmacists
American Society of Health-system Pharmacists
American College of Clinical Pharmacy
American Academy of Colleges of Pharmacy
Southern California Oncology Pharmacists
Rho Chi Pharmaceutical Honor Society

Committee Membership**University of Southern California, School of Pharmacy**

Faculty Search Committee (Norris Institute)	1998
Curriculum Committee	1993
Peer Review Committee	1992
Peer Review Committee (Chairman 1996-1998)	1996-1999
Faculty Search Committee (Pharmaceutical Sciences)	1994-1995
Faculty Search Committee (Pharmacoeconomics)	1995-1997
Faculty Search Committee (Norris Cancer Center)	1998-1999
Faculty Search Committee (Molecular Pharmacology/Toxicology)	1998-1999
Krown Fellowship Ad Hoc Selection Committee	1998-2000
Ad hoc Committee Professional & Service Contract Meeting	1999
Faculty Search Committee (University Hospital)	1999
Faculty Search Committee (Norris Cancer Center)	1999
Faculty Search Committee (Norris Cancer Center)	1999-2000
Pharmacy Faculty Assembly Secretary	1999-2000
Ad Hoc Committee for School of Pharmacy Retreat	2000
Ad Hoc Committee for School of Pharmacy Infrastructure	2000
School of Pharmacy Curriculum and Research Retreat	2000

Consultant Projects

Ciba Geigi	1991-1992
Philadelphia School of Pharmacy	1993-1995
Amgen Corporation	1992-1996
Sandoz Pharmaceuticals	1993-1994
Health Dimensions	1992-1999
Cutter Pharmaceuticals	1993-1995
Bayer Pharmaceuticals	1995-1998
Novartis Pharmaceuticals	1997-1998
Bayer Biologicals	1996-1998
Roche Pharmaceuticals	1995-1998
Dupont Pharma	1997
MedImmune	1996-1998
Bristol Myer Squibb	1995-1998
Agouron Pharmaceuticals	1996-present
Glaxo-Wellcome	1997-present
Gay and Lesbian Specialty Clinic	1998- present
TAP Pharmaceuticals	1999-2000
Pfizer Pharmaceuticals	1997-present
Bayer Biologicals	2000-present

Services with Professional Societies

California Society of Health-system Pharmacists	Editorial Advisory Board
	Educational Team Member
Southern California Oncology Pharmacists	Newsletter Editor
California Society of Health-system Pharmacists	Continuing Education
American Journal of Hospital Pharmacists	Guest Editor
American Pharmacist's Association	Guest Editor

Journal Editorship

American Journal of Hospital Pharmacist	1993	Guest Editor
OncoScope	1994-1995	Editor
California Journal of Health-system Pharmacists	1996-1998	Editorial Advisory

Journal Reviewer

Hospital Pharmacy	1996 to present
Journal of Pharmaceutical Research	1996 to present
California Journal Health Systems (CJHP)	1995 to present
Pharmacotherapy	1995 to present
American Journal of Health-system Pharmacists	1992 to present
Journal of Drug Targeting	1994 to present
OncoScope (Newsletter of SCOPG)	1994 to 1996

GRANT REVIEWER:

Woman's Health Grant	1996
----------------------	------

HONORS/AWARDS:

March of Dimes Research Fellowship	1979-1982
Rho Chi Honor Society	1985 to present
Paper of the Year Award	1997
Fellow of California Society of Health System Pharmacist	1998
Fellow of American Society of Health System Pharmacists	2000

AREAS OF RESEARCH INTERESTS

- 1 Immunodynamics of cytokines (i.e. CSFs and interleukins) and biological response modifiers
- 2 Antiviral therapy to treat human T-lymphotropic virus I (HTLV-I) associated acute T-cells leukemia/lymphoma and human immunodeficiency virus (HIV).
- 3 Effects of HIV on Type IV hypersensitivity reaction towards drugs.
- 4 Pharmacodynamics of antineoplastic drugs with tumor response.
- 5 Molecular Mechanism of Drug interaction

Research Support

2000 to present	Consultant Funding: Health Resource Service Administration (HRSA): Department of Health and Human Services (DHHS) Pharmacology of Antiretroviral Agents	Direct \$24,184
2000 to present	Investigator Funding: Dura Pharmaceuticals Pharmacokinetics and Pharmacodynamics of Cefepime in Cystic Fibrosis Patients	Direct \$24,000

1999 to present	Principle Investigator Funding: Merck IDV in Combination with RTV in HIV Patients	Direct \$15,000
1999 to present	Investigator Funding: TAP Pharmaceutical DUE of Proton Pump Inhibitor and H2 blockers in a County Facility	Direct \$30,000
1999 to present	Investigator Funding: Merck Pharmaceutical Cost Impact of HIV: A Natural History Progression Study	Direct \$42,000
1998 to present	Investigator Funding: Dupont Pharma Effect of substituting efavirenaz for protease inhibitor therapy in patients at increase risk for cardiovascular complications due to HIV associated metabolic disorders	Direct: \$62,000
1998 to present	Principal Investigator Funding: Glaxo/Wellcome The Use of Triple Nucleoside Analogs in HIV Patients Co-Infected with Mycobacterium Tuberculosis	Pending Direct: \$89,000
1997 to 1999	Principal Investigator Funding: The Liposome Company Cost Comparison of Amphotec and Abelcet.	Direct: \$15,000
1995 to 1997	Co-Investigator Funding: MedImmune Clinical and pharmacoeconomic impact of cytomegalovirus immunoglobulin in renal transplantation.	Direct: \$30,000
1995 to 1997	Co-Investigator Funding: Syntex/Roche Clinical and pharmacoeconomic impact of oral ganciclovir in patients with advance AIDS.	Direct: \$80,000
1994 to present	Principal Investigator Funding: Schering Plough Effect of Interferon- α 2b in Combination with Zidovudine in Patients with Human Immunodeficiency Virus and Hepatitis C Virus.	Direct: \$15,000
1993 to present	Principal Investigator Funding: California Collaborative Treatment Group Trimethoprim/Sulfamethoxazole associated generalized cutaneous reaction.	Direct: \$7750
1993 to 1994	Co-Investigator Funding: R.W. Johnson A multicenter, active controlled, randomized study to evaluate the safety, and efficacy of levofloxacin versus ceftriaxone sodium or cefuroxime axetil in the treatment of community-acquired pneumonia in adults.	Direct: \$10,000
1992 to 1993	Principal Investigator Funding: Amgen Incorporated "Effect of Filgrastim on neutrophils derived from patients with severe community acquired pneumonia"	Direct: \$10,165
1991 to 1993	Principal Investigator Funding: Synergen Corporation "Effects of interleukin-1 receptor antagonist on AIDS-Kaposi's sarcoma"	Direct: \$5,000

1991 to 1992	Co-Principal Investigator Funding: Synergen Corporation "A study to evaluate the dose-response relationship of human recombinant interleukin-1 receptor antagonist (IL-1RA) in the treatment of sepsis"	Direct: \$7,500
1991 to 1992:	Co-Principal Investigator Funding: National Cancer Institute "Immunostimulating Activity of Antimicrobials on Lymphokine Activated Killer cells"	Direct: \$5,000
1990 to 1992	Principal Investigator Funding: NIH Biomedical Research Study Grant. "The phagocytic potential and bactericidal activity of cefodizime in human: A pilot study"	Direct: \$2,500
1990 to 1992	Principal Investigator Funding: NIH Biomedical Research Study Grant "Cyclosporin/Interleukin-2 Induction of Graft versus Tumor Activity in Mice undergoing Syngeneic Bone Marrow Transplantation"	Direct: \$3,000
1989 to 1990	Principal Investigator Funding: NIH Biomedical Research Study Grant . "Mechanism of Stem Cell Cytoprotection to 4-Hydroxycyclophosphamide"	Direct: \$5,000
1989 to 1990	Principal Investigator Funding: NIH Biomedical Research Study Grant. "Antineoplastic Induced Gram Negative Bacteria Resistance"	Direct: \$5,000
1982 to 1984	Co-Principal Investigator Funding : Bristol-Myers Pharmaceutical Corporation. "Reduction of Mitomycin C, Bleomycin and Cisplatin toxicities using liposomal delivery system"	Direct: \$100,000

Non-Peer Review Publications

- 1 Louie S. The Colony Stimulating Factors: Part II: Clinical and Experimental Uses. Pharm Immunol 1990; 3(6) 1-3.
- 2 Louie S. and Miyagi S. New Biologicals in Oncology. Calif J. Hosp Pharm 1990; 2:9-10.
- 3 Jhee SS, Oh JH, Gill MA, and Louie SG. Biological response modifiers in oncology. Calif J Hosp Pharm 1994; 6: 9-10.
- 4 Louie SG. Advances in tumor biology and pharmacotherapy. OncoScope 1994; 1: 2-4
- 5 Louie SG. Review of interferon therapy. OncoScope 1995; 2: 2-3
- 6 Louie SG, Sokolskiy L. The potential of gene therapy. Calif J Health-system Pharmacist 1996; 8: 14-17.
- 7 Louie SG, Wong-Beringer A, Sokolskiy L, Rho JP. Use of liposomes as drug carriers for chemotherapeutic and antifungal agents. Calif J Health-system Pharmacists 1996; 8(6):9-14.

Peer Reviewed Publications

- 1 Louie SG and Jaresko GS. Biological agents in infectious diseases. J Pharmacy Practice 1991; 4: 326-341.
- 2 Gill PS, Masood R, Cai J, Louie SG, Harrington W, Lin G, Law R, and Levine AM Novel Antiviral Therapy for HTLV-I Associated Acute T-Cell Leukemia. Blood 1992; 80: 74.
- 3 Louie SG, Mayebo SM, and Gill PS. Critical drug appraisal: Filgrastim: P & T 1992; 17: 589-611.

- 4 Louie SG and Jung B. Clinical Effects of Biological Response Modifiers. Am J Hosp Pharm. 1993; 50:S10-S18.
- 5 Sahai J and Louie SG. Overview of the Immune and Hematopoietic System. Am J Hosp Pharm. 1993; 50:S4-S10.
- 6 Adams J, Jaresko GS, Louie SG, Sharma O, and Boylen CT. Glutathione concentration in plasma and BAL from AIDS patients with and without established *Pneumocystis carinii* pneumonia. J Med 1993; 24: 337-351.
- 7 Louie SG, Cai J, Law R, Lundadi-Iskandar Y, Lin G, Masood R, Jung B, Gill PS. Antiproliferative effect of Interleukin-1 Receptor Antagonist on Acquired Immunodeficiency-Related Kaposi's Sarcoma. J Acq Immun Def Syn 1994; 8: 455-460/1995.
- 8 Gill PS, Lundadi-Iskandar Y, Louie SG, Tulpule A, Zheng T, Espina B, Besnier JM, Hermans P, Levine AM, Bryant JL, Gallo RC. Human chorionic gonadotropin has antitumor activity in AIDS-related Kaposi's Sarcoma. N Engl J Med 1996; 335: 1261-1269.
- 9 Louie SG, Sung J, and Park S. Kaposi's Sarcoma: New advances in tumor biology and pharmacotherapy. Pharmacotherapy 1997; 17(4) 1073-1083.
- 10 Gill PS, McLaughlin T, Espina B, Tupule A, Louie SG, Lunde-Iskandar Y, Gallo RC. Phase I Study of Human Chorionic Gonadotropin Given Subcutaneously to Patients with Acquired Immunodeficiency Syndrome-Related Mucocutaneous Kaposi's Sarcoma. J Natl Cancer Inst 1997; 89: 1797-1802.
- 11 Louie SG and Huh A. Protease Therapy. Antibiotics for the Clinician 1998; 2: 38-41
- 12 Louie SG, Patel P, Rho JP. Pharmaceutical Agents in 2010. New Horizon 1999; 7: 253-261
- 13 Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson, NF, Brown MA, Orcutt C, Winograd B, Scadden DT. Paclitaxel is safe and effective in the Treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999; 17(6):1876-83,
- 14 Louie SG, Chin AC and Gill MA. Activity of Dalteparin Sodium in Polypropylene Syringes. Am J Health-Sys Pharm 2000; 57: 760-762
- 15 Besinque K, Wong W, Louie SG, and Rho JP. Predictors of Success Rate in the California State Board of Pharmacy Licensure Exam. Am J Pharm Edu 2000; 64: 50-53
- 16 Mesbahi M, Louie SG, Gill M. Treatment of Ulcerative Colitis U.S. Pharmacist 2000; 5: HS35-H46
- 17 Louie SG, Besinque K, Rho JP. Antiretroviral Agents in Lipid Dysregulation in HIV Infected Patients. Antibiotics for the Clinician 2000 (In Press)
- 18 Baydur A, Alsalek M, Louie, SG, Sharma O. Dyspnea in Sarcoidosis and its Relationship to Respiratory Muscle and Lung Function. Chest 2000 (Accepted In Revisions)
- 19 Cupo-Abbott J, Louie SG, Rho JP. Linezolid: A synthetic oxazolidione antimicrobial for treatment of serious gram positive infections. Formulary 2000; 35:

Manuscript In Preparation or Submitted

1. Rho J, Louie SG, and Yu W. Review of liposomal amphotericin B (In preparation).
2. Louie SG, Sokolskiy L, Rho J, Hay J. Pharmacoeconomics impact of cytomegalovirus prophylaxis using oral ganciclovir in advance HIV patients (In preparation)
3. Louie SG, Tupule A, Yoon H, Sokolskiy L, Abang A and Gill PS. Filgrastim requirements in AIDS patients with Kaposi's Sarcoma. (Submitted Cancer)

4. Louie SG, Ung J, Wong D, , Lee KJ. and Rho J. Evaluating Nephrotoxicity Criteria for Lipid Formulation of Amphotericin B (Submitted to J. of Pharmacy Technology: In revisions)

Books And Chapters In Book

1. Louie SG and Rho JP. Pharmacotherapeutics of Biotechnology-Produced Drugs. In Zito S W. Ed. Pharmaceutical Biotechnology A Program Text. Second Edition. Landcaster: Technomic Publishing Company Inc. 1997: 205-232
2. Shen WC, and Louie SG. Immunology for Pharmacists and Pharmaceutical Scientists. Harwood Press. 1998
3. Rho JS, and Louie SG. Handbook on Biotechnology (First Draft Completed)
4. Louie SG and Rho JP. PSAP: Immunology Primer, Module 7 Nephrology-Immunology 1999

Educational Publications

- 1 Biotechnology Resource Catalog
- 2 Critical Issues in the Therapeutic Use of IVIG and Blood Products. 1996
- 3 Overview in Liposomal Technology. Oncology Nursing Society (ONS) 1997

Abstracts And Presentations

- 1) Ling V., Whitney J., Santikarn S., Burlingame A. and Louie S. Protein Sequencing of Bovine Serum Albumin and Insulin Using Cesium LSIMS. UCSF Mass Spectrometry Symposia, 1985. pp 50.
- 2) Zander A, Brittin J, Bermudez M, Lyding J, Huyhn L, Louie S, and Shephard R. Activity of 4-Hydroxycyclophosphamide(4HC) and tumor necrosis factor (TNF) in human bone marrow and breast cancer cells. Exp. Hematology 1989; 17(6) 146.
- 3) Louie S., Nagata R. and Whittle S. Study Module in Bone Marrow Transplantation. Residency Conference in Asilomar 1988. PH 13
- 4) Louie SG, Rahman M, Jaresko GS, Charak B, Mazumder A. Effects of anti-infective on lymphokine activated killer (LAK) cells cytotoxic activity. Pharmacotherapy 1991; 11: 282.
- 5) Jaresko GS, Kennedy D, Adams J, Louie SG, Sharma O, Boylen CT. Glutathione concentrations in plasma and bronchial alveolar lavage samples from AIDS patients with and with out established *Pneumocystis carinii* pneumonia. Pharmacotherapy 1991; 11: 267.
- 6) Kennedy D, Jaresko GS, Adams J, Louie SG, Sharma O, Boylen CT. Glutathione concentration in plasma and BAL from AIDS patients with and without established *Pneumocystis carinii* pneumonia. Third International Conference on bronchoalveolar lavage. Vienna, Italy June 20-22, 1991, pp 385.
- 7) Louie SG, Jeong EW, and Mayebo SL. The use of trans-retinoic acid in a patient with acute promyelocytic leukemia and renal failure. Am J Hosp Pharm 1991; 48: 2234.
- 8) Jaresko GS, Bloedow DW, Louie SG, Pribble JP, Gilman TM, Dodds S.. Recombinant interleukin-1 receptor antagonists in a septic patient undergoing hemodialysis. Pharmacotherapy 1993; 13: 33.
- 9) Mikhail M, Thangathurai D, Kuchta K, Yaker K, Moses J, Mayebo S, Sheybani T, Louie S. Postoperative analgesia for ICU patients: Comparison of ketamine-fentanyl, fentanyl, and morphine by continuous intravenous infusion. Critical Care Med Annual Meeting, 1993.

- 10) Bonacini M, Louie SG, Govinderajan S, Zuckerman E, Mistein S, and Lindsay K. Plasma cytokines in patients with hepatitis C before, during and after interferon therapy: Biochemical and histological correlation. Am. Gastroenterology Society. Chicago, IL 1995.
- 11) Tayeban DT, Mitani G, Louie SG, Harrison E. Subcutaneous Heparin in an Ambulatory Setting. Am Society of Health-system Pharmacists Mid-year Meeting in New Orleans, 1996.
- 12) Sung JCY, Hay J, Louie SG, Popovian R. Cost-effectiveness of cyclophosphamide, doxorubicin, and 5-fluorouracil in pre-menopausal women with lymph node positive, early stage breast cancer. APOR Conference April 1997.
- 13) Louie SG, Yoon H, Gill PG, Kern J. Filgrastim requirements in AIDS patients receiving Taxol. Western States Conference. Asilomar, CA 117, 1997.
- 14) Louie SG, Kakka R, Walker J, Gill M. Involvement of hydroxylamine in sulfamethoxazole cutaneous reactions. Western States Conference. Asilomar, CA 099, 1997.
- 15) Ung J, Wong D, Louie SG, Lee KJ, Rho J. Evaluating Nephrotoxicity Criteria for Lipid Formulation of Amphotericin B 18th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-21, 1998
- 16) Fong S, Rho J, Louie S. Evaluation of HMG-CoA Reductase Inhibitors in a Primary Care Clinic. 18th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-21, 1998
- 17) Hou D, Ung J, Louie SG, Lee KJ, Rho J. Evaluating Nephrotoxicity Criteria for Lipid Formulation of Amphotericin B. ICACC, San Diego, CA September 1998
- 18) Jones BE, Oyata M, Hsu V, Ravos E, Louie S, Currier J. The Efficacy of HAART (Highly Active Antiretroviral Therapy) in HIV positive Tuberculosis (TB) Patients. The American Thoracic Society Conference San Diego, CA April 23-28, 1999
- 19) Albert C, Louie SG, Rho J. Decision Analysis of Amphotericin and Amphotericin-Lipid Complex. 19th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-20, 1999
- 20) Aminmanizani A and Louie SG. Molecular Mechanism of Sulfamethoxazole-Mediated Toxicity. 19th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-20, 1999
- 21) Montgomery M, Beringer P, Louie SG, Gill M. Predictive Performance of Various Creatinine Clearance Equation. 19th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-20, 1999
- 22) Montgomery M, Beringer P, Louie SG, Gill M. Predictive Performance of Various Creatinine Clearance Equation. ACCP Annual Meeting, Kansas City, Kansas, 1999
- 23) Johnson D, Sattler F, Qian JL, Briggs W, Louie SG, Dube M. Incidence of Hypertension in HIV Patients with Fat Remodeling. 13th Antiretrovirus and Opportunistic Infections Conference 2000
- 24) Pranata I, Johnson D, Kong H, and Louie S. Effect of Nelfinavir Nevirapine Combination as a HAART Salvage Regimens in HIV patients who Failed on Initial HAART. 10th World AIDS Conference, Dublin South Africa, 2000
- 25) Pranata I, Johnson D, Kong H, and Louie S. Effect of Nelfinavir Nevirapine Combination as a HAART Salvage Regimens in HIV patients who Failed on Initial HAART. 20th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-20, 2000

- 26) Nguyen T, Tran J, Mitani G, and. Louie SG, .Amiodarone-induced Thyroid Dysfunction Influence on Oral Anticoagulation Therapy. 20th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-20, 2000
- 27) Kwon H, Louie SG Effect of highly active antiretroviral therapy in HIV-infected patients on survival20th Annual Western States Conference for Pharmacy Residence, Fellows, and Preceptors, Pacific Grove CA, May 17-20, 2000

Invited Conference Presentations

1. Immunosuppressive Therapy: Current Clinical Practice and Future Outlook. In Symposia; First Annual Southern California Transplantation for Transplant. Laguna Niguel, CA. November 1992.
2. Impact of Biological Response Modifiers in the Clinical Arena. Biological Response Modifiers: Challenges and Opportunities in the 1990s. Canadian Symposia. Orlando, FL. December 1992.
3. Clinical Impact of Biological Response Modifiers. Biological Response Modifiers: Clinical Impact and Pharmacoeconomics Issues. American Society of Hospital Pharmacists. Orlando, FL. December 1992.
4. Current Status in the Management of Antiemetic Therapy. University of Southern California 36th Annual Postgraduate Refresher Course. Maui, HI. 1993.
5. Biological Response Modifiers. American Society of Consultant Pharmacist Annual Meeting. Boston, MA. August 1994.
6. Biotechnology advances in AIDS treatment. SunHealth Biotechnology Institute. Charlotte, NC. August 1994.
7. Advances in Drug Delivery System in the Homecare Setting. Palm Spring, CA. October 1995.
8. Chemotherapy Update in the Homecare Setting. American Society of Hospital Pharmacists. Homecare Meeting. Boston, MA. July 1995.
9. Myocarditis: An autoimmune model for immune modulation. In the Symposia: The Efficacy and Safety of Biological Products. Dallas, TX. October 1995.
10. New advancement in the treatment of AIDS and AIDS related diseases. SunHealth Biotechnology Symposia. Charlotte, NC. September 1995.
11. Myocarditis: An autoimmune model for immune modulation. In the Symposia: The Efficacy and Safety of Biological Products. Scottsdale, AZ. April 1995.
12. Advances in immunomodulation of acute and polyneuropathy. In the Symposia: The Efficacy and Safety of Biological Products. Scottsdale, AZ. April 1995.
13. The role of cytokines in cancer biology. California Society of Healthcare-system Pharmacists (CSHP) Focus Seminar. Newport Beach, CA. March 1996.
14. Advances in dosage intensification: A Focus on non-Hodgkin's lymphoma and breast cancer. California Society of Healthcare-system Pharmacists (CSHP) Focus Seminar. Newport Beach, CA. March 1996.
15. Current Advances of HIV Pathogenesis and Pharmacotherapy. CPhA Mid-year Education Fair. Reno, NV. September 1996.
16. Overview in Liposome Technology. Oncology Nursing Society. New Orleans, LA. May 1997.
17. Biotechnology Developments in HIV Therapy. CSHP Seminar. San Jose, CA. October 1997.
18. Marijuana: Governmental Obstruction or Just Junk? ASHP Midyear Meeting. Atlanta, GA. December 1997.

19. What is new in Antibiotic Therapy. Orlando, Florida. University Learn System Symposia, June 1998
20. Advances in Cancer Therapy. Orlando, Florida, University Learning System Symposia, June 1998
21. Update on AIDS: Real Progress or Just the Same Old Thing. California Employee Pharmacists Association Symposium, West Los Angeles, CA July 1998
22. Drug Management When to Use a HMG-CoA Reductase Inhibitor. Los Angeles County Physician Conference. Long Beach Aquarium, CA August 1998
23. Biotechnology: Coming for the Ride? California Employee Pharmacists Association Symposium. Buena Park, CA February 1999
24. Biotechnology: Coming for the Ride? California Employee Pharmacists Association Symposium. San Diego, CA March 1999
25. Molecular Mechanism of Drug Interactions in HIV Patients: Good or Bad? AIDS Clinical Trials Group (ACTG) Symposium in Drug Therapy. April 1999
26. Drug Interactions in HIV Patient. Second Annual Update on HIV Therapy. Ryan White Conference. Tucson, Arizona June 1999
27. Drug interactions in HIV setting: A pharmacokinetics point of view. Southern California College of Clinical Pharmacists CA July 1999
28. Update on HIV Therapy. University Learning System Symposia on Therapeutic Updates. Las Vegas, NV July 1999
29. Cytokine-induced on Kaposi's Sarcoma Proliferation. Frontiers in Drug Development. Pasadena, CA July 1999
30. Pharmacoeconomics Impact of HAART. Florida Correctional Agency Healthcare Conference. Orlando, Florida, 1999
31. The Effect of Aggrastat on Coronary Heart Disease: Strategic Plans for the Future. Ritz Carleton Marina Del Rey, CA September 1999
32. Future of Pharmacotherapy in the Critical Care Arena. CSHP Focus. Marriott Oakland, CA March 2000
33. Health Economics and Outcome Research Training: Symposium. Minneapolis, Minnesota May 2000
34. Health Economics and Outcome Research Training: Symposium. Costa Mesa, CA June 2000
35. Current Understanding of Treatment for Hepatitis A and B. Symposium, Loew Bay Resort, Coronado, CA 2000

Invited Lectures

- 1 Cancer Metastases: "Just Breaking the Collagenase Barrier?" UCSF Cell Biology Seminar 1985.
- 2 Oncogenes: "Living in a Cancerous Cage": UCSF Cell Biology Seminar 1986.
- 3 Ifosfamide: A New Analog of Cyclophosphamide: UCSF Student Conference 1986.
- 4 Antibiotics in Opportunistic Infections In AIDS: UOP Pharmacy Student Seminar 1987
- 5 "Where is Bone Marrow Transplantation going?" UOP Pharmacy Student Seminar 1987.
- 6 Ciprofloxacin: "Fluorinated Quinolones A New Class of Antibiotics": Miles Pharmaceutical Seminar 1988.

- 7 Granulocyte/Macrophage Colony Stimulating Factor(GM-CSF): Panacea or Pandora's Box: Pharmacy Seminar at USC. Los Angeles, CA. 1988.
- 8 Bone Marrow Transplantation: "The Panacea for Hematological Diseases?" Western States Resident Conference 1988.
- 9 Bone Marrow Transplantation: Increase Modality for Hematological Diseases. Children's Hospital in Los Angeles: Pharmacy Seminar. Los Angeles, CA. 1989.
- 10 Introduction to the Immune System: How Immunoglobulin Can Enhance Immune Deficient Patients: Kaiser Hospital in Fontana, Fontana, CA. 1989.
- 11 Introduction to the Immune System: How Immunoglobulin Can Enhance Immune Deficient Patients: Loma Linda University, Los Angeles, CA. 1989.
- 12 Biotechnology of vaccines: Uses in oncology and microbiology. USC School of Graduate School of Pharmacy. Los Angeles, CA. 1990.
- 13 Immunotherapy in cancer. USC School of Graduate School Seminar. Los Angeles, CA. 1990.
- 14 Granulocyte-macrophage colony stimulating factor (GM-CSF) uses in oncology and bone marrow transplantation. San Francisco, CA. 1990.
- 15 Overview of the immune system: clinical uses of immunoglobulins in immunodeficient patients. Kaiser Permanente Clinical Coordinator Meeting, Oakland, CA. 1991.
- 16 Clinical and experimental uses of hematopoietic growth factors, Kuaialani Medical Center. Honolulu, HI. 1991.
- 17 The use of hematopoietic growth factors in bone marrow transplantation and chemotherapy-induced neutropenic patients. Queens Medical Center. Honolulu, HI. 1991.
- 18 Hematopoietic growth factors: Clinical applications and future implications. Hawaii Society of Hospital Pharmacy Annual Meeting. Kona, HI. 1991.
- 19 Hematopoietic growth factors: Biotechnology and the Hospital Pharmacists: Selected Topics. Scottsdale, AZ. June 8-9, 1991.
- 20 National Nosocomial Surveillance Research Group Teleconference. Los Angeles, CA. 1991.
- 21 In vitro comparison of colony stimulating factors: Medical Oncology Grand Round. Saint Vincent Medical Institute. Los Angeles, CA. June 1991.
- 22 Molecular Mechanism of AIDS-related Kaposi's Sarcoma and Immunomodulation. University of Pacific Graduate Seminar. Stockton, CA. 1992.
- 23 Colony Stimulating Factor: Clinical Impact and Economic Considerations. California Society of Hospital Pharmacists. Anaheim, CA. October 1992.
- 24 Recent advances in immunotherapy for Guillain Barre' Syndrome. In Symposia; Immunoglobulin as Immunomodulators in Infections and Autoimmune Disease. Marina del Rey, CA. October 1992.
- 25 Molecular Mechanism and Immunomodulation of AIDS-related Kaposi's Sarcoma and Immunomodulation. Toxicology and Molecular Pharmacology Institute Seminar, University of Southern California. Los Angeles, CA. 1992.
- 26 The use of immunoglobulin in Autoimmune Disease: What are the Clinical Cost Implications. In Symposia; Immunoglobulin: Beyond Replacement Therapy. San Francisco, CA. June 1992.

- 27 Review of the immune system and the use of immunoglobulin in immunodeficient patients. Quadra Country CSHP Chapter. Palo Alto, CA. April 1992.
- 28 The Use of Immunoglobulin in Autoimmune Diseases. In Symposia; Advances in Immunomodulation. Arlington, VA. April, 1992.
- 29 An Overview of the Hematopoietic System and The Future Use of Colony Stimulating Factors. In Symposia; Biotech Biologicals for the Decade 1990's:University Of Southern California. Los Angeles, CA. February 1992.
- 30 Practical Issues in Biotechnology. In Biotechnological Agents: Pharmaceutical Care Practice Issues. New York Council of Hospital Pharmacy. New York, NY. 1993.
- 31 Advances and Treatment in the Pathophysiology of Polyneuropathy: In Current Concepts in Immunoglobulin Therapy. Phoenix, AZ. 1993.
- 32 Latest Concept on Cancer Chemotherapy. Downey Community Hospital/Rio Hondo Hospital. Downey, CA. 1993.
- 33 Myeloid Growth Factors: Biological and Clinical Opportunities and Challenges. Napa Valley Society of Hospital Pharmacists. Napa Valley, CA. 1993.
- 34 Latest Word in Transplantation. University of Southern California 36th Annual Postgraduate Refresher Course. Maui, HI. 1993.
- 35 Cytokines in Patients with Acquired Immunodeficiency Syndrome (AIDS). Cedar Sinai Medical Center, Los Angeles, CA. 1993.
- 36 The Use of Biological Response Modifiers in Oncology/Hematology. Huntington Memorial Hospital. Pasadena, CA. 1993.
- 37 Current Advances in Oncology: University of California in San Francisco Continue Education Program. Pasadena, CA. 1993.
- 38 Current Advances in Transplantation: Balance Between Immunosuppression and Infections. Veteran Hospital in San Diego. San Diego, CA. 1993.
- 39 Advances in tumor biology and pharmacotherapy: Emphasis on p53 tumor suppressor gene. Southern California Oncology Pharmacy Group. Orange, CA. January 1994.
- 40 Therapeutic advances in the administration of high dose chemotherapy. Saint Vincent Oncology Grand Rounds. Los Angeles, CA. May 1994.
- 41 Role of the Practicing Pharmacist in Cytokine Therapy. "The Power of a Minute Patient-Pharmacist Consultation and Financial Management for the Practicing Pharmacist". University of Southern California School of Pharmacy Continuing Education. Indian Wells, CA. 1993.
- 42 Advances in Immunotherapy: The use of high dose immunoglobulin. Saint Vincent Medical Ground Rounds. Los Angeles, CA. June 1994.
- 43 Advances in stem cell therapy and bone marrow transplantation: Napa Valley Society of Society of Hospital Pharmacists. Napa, CA. July 1994.
- 44 Advances in cancer biology and treatment. CIGNA Healthcare Chemotherapy Conference. Los Angeles, CA. August 1994.
- 45 Clinical uses of colony stimulating factors. Travelers Insurance. San Antonio, TX. September 1994.
- 46 Advances in Diabetes Therapy. Downey Community Hospital Nursing Conference. Downey, CA. January 1995.

- 47 Advances in chemotherapy and immunotherapy for oncology. CIGNA Healthcare. Los Angeles, CA. January 1995.
- 48 Pharmaceutical care in patients receiving hematopoietic factors. Pharmacy Grand-Rounds at Saint Francis Hospital. Honolulu, HI. July 1995.
- 49 Advances in cytokine therapy in the 1990's. San Diego Society of Hospital Pharmacist. San Diego, CA. August 1995.
- 50 What's on the Horizon? New Drugs and New Challenges. Academy of Manage Care Pharmacy. University of Southern California. Los Angeles, CA. October 1995.
- 51 Advances in biotechnology in the treatment of cancer and viral infections. Southern California Society of Vietnamese Pharmacists. Garden Grove, CA. November 1995.
- 52 Emerging issues regarding immunoglobulin. Armour Pharmaceuticals. Teleconference, October to December 1995.
- 53 Advances in immunoglobulin therapy. Teleconference, October to December 1996.
- 54 Update on Taxol. University of Southern California/Los Angeles County Hospital AIDS Research Unit. Los Angeles, CA. January 1996.
- 55 Molecular mechanism of drug toxicity. Infectious Disease Grand Round, Department of Internal Medicine. University of Southern California. Los Angeles, CA. January 1996.
- 56 Advances in colony stimulating factor in oncology and infectious disease setting. Dakota Heartland Society of Healthcare System Pharmacists. Fargo, ND. February 1996.
- 57 Methods of Liposome Preparations. CSHP Quadra County Society of Health-system Pharmacists. San Jose, CA. March 1996.
- 58 Advances in HIV Pharmacotherapy. CEPA. San Fernando Valley, CA. March 1996.
- 59 Advance in Protease Inhibitors. CEPA West Los Angeles, CA. March 1996.
- 60 Advances in HIV Pharmacotherapy. CEPA. San Diego, CA. June 1996.
- 61 Advances in HIV Pharmacotherapy: Emphasis on Protease Inhibitors. Southern California MediCal Association. Los Angeles, CA. June 1996.
- 62 Overview of pharmacoconomics: How to do it right? Orange County Society of Hospital Pharmacy. Anaheim, CA. July 1996.
- 63 Advances in interferon modulation and therapy. Navy Hospital. San Diego, CA. January 1997.
- 64 Advances in Cytokine Therapy in Oncology and Infectious Disease Setting. Fresno Society of Hospital Pharmacy. Fresno, CA. February 1997.
- 65 Advances in HIV therapy. Los Angeles CA. April 1997.
- 66 Molecular basis of drug metabolism in patients with HIV. AIDS Clinic Medical Grand Round, April 1997.
- 67 Cost effectiveness of Cytogam® in patients receiving renal transplants. Seabrook, SC. May 1997.
- 68 Interferon's role in infection and cancer therapy. Los Angeles, CA. May 1997.
- 69 Overview of HIV/AIDS and new developments. Loews Hotel. Santa Monica, CA. May 1997.

- 70 Overview in Antifungal Therapy. Family Practice Grand Rounds: Martin Luther King Medical Center. Los Angeles, CA. June 1997.
- 71 Advances in Antiretroviral Therapy: Medical Grand Rounds: Olive View Medical Center. July 1997.
- 72 New Advances in HIV Therapy: What are the Pharmacists' Role. Las Vegas, NV. July 1997.
- 73 Update on Antiretroviral Therapy. Los Angeles, CA. October 1997.
- 74 Double Protease Combination in HIV Therapy: Los Angeles CA. November 1997.
- 75 New Advances in interferon Therapy, Beverly Hills CA November 1997
- 76 New developments in HIV therapy (1592U89 and 141W92) Los Angeles, CA. November 1997.
- 77 HIV Therapy: Exploiting Drug Interactions. November 1997.
- 78 HIV: What is it? And How to Treat It. Beverly Hill, CA. November 1997.
- 79 Antiretroviral Therapy: Outcomes Based Therapy. December 1997.
- 80 Update on Antibiotics. January 1998, San Marino, CA 1998
- 81 Antibiotics: New Development in the Horizon. Los Angeles, CA January 1998
- 82 New Advances in Quinolone Therapy. Lake Arrowhead, CA February, 1998
- 83 New Advances in Antibiotic Therapy, San Fernando Valley, CA February 1998
- 84 Quinolones in long-term facility. Paramount, CA February, 1998
- 85 Update on interferon therapy for viral infections. Beverly Hills, CA February, 1998
- 86 5th Retroviral Conference: Emphasis on Abacavir. Los Angeles, CA February, 1998
- 87 Update on the 5th Retroviruses and Opportunistic Infections Conference, Pasadena, CA March 1998
- 88 Developments in Quinolone Therapy in Long-Term Care Facilities. Fullerton, CA. March 1998
- 89 Interferon Therapy in Cancer and Viral Infections. Medical Grand Rounds. Olive View Medical Centers. April 1998
- 90 Molecular Mechanism of Atherosclerosis. Update on the Management of Lipid Therapy Los Angeles, CA March 1998
- 91 Quinolone Therapy: The Introduction of Trovafloxacin. Los Angeles, CA April 1998
- 92 AIDS Therapy: A Pharmacists Perspective. VA Wadsworth. Los Angeles CA, May 1998
- 93 What is New in Antibiotic Therapy. Encino, CA June 1998
- 94 Advances in HIV Therapy: Is There Anything New? Los Angeles County Jail Medical Grand Rounds, July 1998
- 95 Update on AIDS: Real Progress or Just the Same Old Thing. California Employee Pharmacists Association Symposium, Studio City, CA July 1998
- 96 Update on 12th World AIDS Conference. Los Angeles CA July 1998

- 97 Update on 12th World AIDS Conference: Combination Protease Inhibitor Therapy: Exploiting Drug Interactions. Los Angeles, CA August 1998
- 98 Update on the Geneva Conference: Protease Inhibitors in Combination with nNRTI, Pasadena CA August 1998
- 99 Update on AIDS: Real Progress or Just the Same Old Thing. California Employee Pharmacists Association Symposium, Irvine, CA, August 1998
- 100 Update on AIDS: Real Progress or Just the Same Old Thing. California Employee Pharmacists Association Symposium, San Diego, CA, September 1998
- 101 Treatment for Mycobacterium avium-complex. Los Angeles, CA October 1998
- 102 HAART Therapy: the Good, the Bad and the Ugly. Gay and Lesbian Health care Clinic, November 1998
- 103 Update of HIV Therapy: Emphasis on nNRTI Therapy. East Los Angeles and Hollywood California of Pharmacy Association (CPhA). Los Angeles, CA 1999
- 104 HAART Therapy: Combination Protease Inhibitor Therapies. Los Angeles, CA January 1999
- 105 Cytomegalovirus in the immunocompromised Host. Los Angeles, CA February 1999
- 106 Fortovase in the Era of HAART. Los Angeles, CA March 1999
- 107 Double Protease Inhibitor in HIV HAART. Medical Grand Rounds. Jeffery Goodman HIV Clinic. March 1999
- 108 The Contribution of Efavirenz in HIV Patients. Los Angeles, CA April 1999
- 109 Drug Interaction in HAART: Good or Bad. Honolulu, Hawaii April 1999
- 110 Update on HIV Therapy: An Emphasis on Agenerase. Pasadena, CA June 1999
- 111 Update on Nelfinavir in the Fight Against HIV-infection. Pasadena, CA June 1999
- 112 Update on 5-a-reductase therapy. Monterey Park, CA July 1999
- 113 Drug interactions in HIV setting: A pharmacokinetics point of view. Los Angeles CA July 1999
- 114 Update in HIV Pharmacotherapy, University Learning System Conference. Las Vegas, CA July 1999
- 115 Efavirenz: A New Player in the HAART. Los Angeles, CA July 1999
- 116 Agenerase: New Weapon in the Fight against HIV. 5P21 Grand Rounds, Los Angeles CA July 1999
- 117 Mechanism of Drug Interaction for the Infectious Disease Practitioner. Grand Rounds, Los Angeles County-University of Southern California. August 1999
- 118 Overview of Cholesterol Biosynthesis and Metabolism. Los Angeles, CA August 1999
- 119 Mitochondria toxicity in HIV and HAART. Gay and Lesbian Center: Grand Rounds, October, 1999
- 120 Lipodystrophy: Mitochondria toxicity or Protease Inhibitor Adverse Effect? Alta Med Physician Group. November 1999
- 121 New Advances in the Treatment of Arthritis: A Look into Cyclooxygenase Specific Inhibitor. Los Angeles, CA November 1999

- 122 Cholesterol Biosynthesis and Metabolism: Impact of HMG CoA Reductase Inhibitor. Fullerton, CA November 1999
- 123 Role of Azithromycin in the HIV Setting. Laguna Niguel, CA November 1999
- 124 Update on Drug Interaction in HIV Setting. Los Angeles, CA November 1999
- 125 Update on Non-nucleoside reverse transcriptase inhibitor. Los Angeles, CA December 1999
- 126 HIV Therapy in the New Millennium. Pasadena CA December 1999
- 127 Molecular Mechanism of Nucleoside-Mediated Mitochondrial Toxicity: An Insight Into HIV-Associated Lipodystrophy. University of Southern California, Maternal Child Grand Rounds. Los Angeles, CA 2000
- 128 Closer Look into Lipid Formulation Therapy, Los Angeles CA 2000
- 129 Perspective of Antifungal Therapy. Beverly Hills, CA February 2000
- 130 Comparisons of the Various Macrolides. Saint Francis Hospital Pharmacy Grand Round, Los Angeles, CA February 2000
- 131 What is the difference between quinolones and macrolide therapy. Beverly Hills, CA March 2000
- 132 Molecular Mechanism of Lipodystrophy. Hollywood, CA March 2000
- 133 Cyclooxygenase Inhibitors in Rheumatoid Arthritis and Cancer. Pasadena CA March 2000
- 134 Molecular Mechanism of Lipodystrophy: Do we know more now than a year ago? Hollywood, CA March 2000
- 135 Delavirdine: Rebirth of a Non-nucleoside reverse transcriptase inhibitor Los Angeles CA March 2000
- 136 Update in Drug Synergy: A perspective into Drug Interactions. Los Angeles, CA April 2000
- 137 Exploiting Drug Interactions to Extend Drug Synergy: Are They Different Sides to the Same Coin? Los Angeles, CA April 2000.
- 138 Advances in Viral Treatment in a Post-Modern Day Era. Beverly Hills, CA June 2000
- 139 What determines Success in HIV Therapy? Grand Rounds Maternal Child Unit University of Southern California School of Medicine, Los Angeles CA June 2000
- 140 What Determines Failure? How Do To Manage Failures? Grand Rounds: Rand Schrader HIV Clinical. University of Southern California School of Medicine, Los Angeles CA July 2000